BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 28, 2026
Home » Newsletters » BioWorld

BioWorld

Jan. 16, 2026

View Archived Issues
Natural killer cell attacking cancer cell

Immunitybio’s CAR-NK shows complete responses in Waldenström’s

Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), used in combination with anti-CD20 drug rituximab, led to durable complete responses without lymphodepletion. Read More
Tylenol Extra Strength bottle and white caplets

New review finds no evidence Tylenol in pregnancy raises autism risk

A new systematic review and meta-analysis of studies looking at a possible association between Tylenol (acetaminophen) use in pregnancy and neurodevelopmental disorders in children concludes there is no evidence of any meaningful risk. The study was carried out by researchers in the U.K., Italy, Sweden and Norway, in response to U.S. Secretary of Health and Human Services Robert Kennedy saying last September that there is a link. Unless medically necessary, it is “irresponsible” to take Tylenol during pregnancy, Kennedy said. Read More
China flag and vial

Six drugs to watch in China for 2026

As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead. Read More
Gray and green glass dollar symbols with arrow pointing up

December blockbusters push biopharma deal value to record high

After only three $1 billion-plus biopharma deals in November, December saw 14 blockbuster deals worth a total of $21.92 billion, including four deals worth more than $2 billion. Read More
3D illustration of cluster of fat cells

Fat tissue subtyping gives functional insights

Once it was considered to be more or less a passive energy-storing device that could double as a cushion. But increasingly, fat is conceptualized as an endocrine organ as much as a tissue type. Now, separate research groups have reported new insights into the functional roles of different fats based on their anatomical location and functional characteristics. Read More

Former Emergent CEO faces insider trading allegations

The New York attorney general’s office has filed suit against the former CEO of Emergent Biosolutions Inc., alleging insider trading, while at the same time announcing a settlement with the company, which agreed to pay $900,000 in penalties for approving the illegal trading plan. The lawsuit stems from reports of vaccine contamination at the company’s manufacturing plant during the height of the COVID pandemic. Read More

Holiday notice

BioWorld's offices will be closed in observance of Martin Luther King Jr. Day in the U.S. No issue will be published Monday, Jan. 19. Read More

BioWorld 2025 Year in Review

BioWorld looks back at the year's biggest news. Find all of our 2025 Year in Review articles here. Read More

Appointments and advancements for Jan. 16, 2026

New hires and promotions in the biopharma industry, including: Flashpoint, Viromissile. Read More

Financings for Jan. 16, 2026

Biopharmas raising money in public or private financings, including: Bridgebio, Qurient. Read More

In the clinic for Jan. 16, 2026

Clinical updates, including data readouts and publications: Gradalis, HMNC, J&J, Medicenna, Neurocrine, Ocugen, OS Therapies, Teva, Vaxart. Read More

Other news to note for Jan. 16, 2026

Biopharma happenings, including deals and partnerships, and other news in brief: Agenus, AFT, Alfasigma, Alveus, Eagle, Innovative Molecules, LXO, Stablepharma, Zydus. Read More

Regulatory actions for Jan. 16, 2026

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Adolore, Eli Lilly, Sanofi, Santhera. Read More
Illustration of a letter traveling on a paper plane

Notice of email fulfillment change

Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. Call us:
  • Americas: 855-258-3279
  • Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.
Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing